US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ABVC BioPharma, Inc.

2.75

+0.350014.58%

Post-market: 2.800.0500+1.82%19:32 EDT

Volume:320.00K

Turnover:845.76K

Market Cap:44.69M

PE:-12.27

High:2.77

Open:2.39

Low:2.39

Close:2.40

Loading ...

Overview Company News Filings

Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study

Why Shares of Axsome Therapeutics Slumped Today

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression

Press Release: Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Buy Rating Affirmed for Axsome Therapeutics Amid Promising ADHD Treatment Results and Strategic Market Positioning

Axsome Therapeutics' Phase 3 Trial of Solriamfetol to Treat ADHD Meets Primary Endpoint

MT Newswires Live

Press Release: Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

We Are Turning Too Many People into Medical Patients -- WSJ

Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

BRIEF-ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma

JNJ Halts Development of Depression Drug Over Efficacy Concerns

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs

NetraMark Showcases AI Breakthroughs in Clinical Trials for MDD and Schizophrenia

Cingulate reports safety results from final Phase 3 trials for CTx-1301

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

Strategic Adjustments and MDD Focus Drive Buy Rating for Neumora Therapeutics Amid Study Delays

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ABVC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ABVC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABVC\",,,,,undefined,":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":2.75,"timestamp":1754078400000,"preClose":2.4,"halted":0,"volume":320002,"hourTrading":{"tag":"盘后","latestPrice":2.8,"preClose":2.75,"latestTime":"19:32 EDT","volume":178,"amount":495.15,"timestamp":1754091169014},"delay":0,"floatShares":13488792,"shares":16250952,"eps":-0.224214,"marketStatus":"Market Closed","change":0.35,"latestTime":"08-01 16:00:00 EDT","open":2.39,"high":2.77,"low":2.39,"amount":845757.765953,"amplitude":0.158333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.224214,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754294400000},"marketStatusCode":7,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":2.4,"preHourTrading":{"tag":"盘前","latestPrice":2.39,"preClose":2.4,"latestTime":"09:29 EDT","volume":13,"amount":31.2500019,"timestamp":1754054979639},"postHourTrading":{"tag":"盘后","latestPrice":2.8,"preClose":2.75,"latestTime":"19:32 EDT","volume":178,"amount":495.15,"timestamp":1754091169014},"volumeRatio":1.5342491774483324,"impliedVol":2.1893,"impliedVolPercentile":0.625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABVC\",,,,,undefined,":{"symbol":"ABVC","floatShares":13488792,"roa":"-10.91%","roe":"-42.42%","lyrEps":-0.419983,"volumeRatio":1.5342491774483324,"shares":16250952,"dividePrice":0,"high":2.77,"amplitude":0.158333,"preClose":2.4,"low":2.39,"week52Low":0.4,"pbRate":"8.27","psRate":"87.91","week52High":5.48,"institutionHeld":0,"latestPrice":2.75,"eps":-0.224214,"divideRate":0,"volume":320002,"delay":0,"ttmEps":-0.224214,"open":2.39,"prevYearClose":0.59,"prevWeekClose":3.01,"prevMonthClose":2.4,"prevQuarterClose":2.225,"fiveDayClose":3.01,"twentyDayClose":3.11,"sixtyDayClose":1.15},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ABVC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524145174","title":"Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2524145174","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524145174?lang=en_us&edition=fundamental","pubTime":"2025-04-02 17:05","pubTimestamp":1743584724,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazee...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/neumora-therapeutics-inc-faces-setbacks-with-delayed-mdd-program-and-discontinued-bipolar-depression-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/neumora-therapeutics-inc-faces-setbacks-with-delayed-mdd-program-and-discontinued-bipolar-depression-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","NMRA","BK4007","BK4139"],"gpt_icon":0},{"id":"2524314147","title":"Why Shares of Axsome Therapeutics Slumped Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2524314147","media":"Motley Fool","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524314147?lang=en_us&edition=fundamental","pubTime":"2025-04-02 01:23","pubTimestamp":1743528180,"startTime":"0","endTime":"0","summary":"A phase 3 trial didn't go according to plan.Management is pushing forward with another phase 3 on the back of some positive data in the trial.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/01/why-shares-of-axsome-therapeutics-slumped-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4505","BK4139","BK4588","ESS","BK4007","ABVC","BK4585","AXSM","BK4215","BK4597"],"gpt_icon":0},{"id":"2524619454","title":"Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524619454","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524619454?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"Results support continued development in MDD with concomitant EDS; Phase 3 trial planned in 2025 Approximately 50 percent of MDD patients experience EDS1, highlighting high unmet need NEW YORK, April ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053170/33090/en/Axsome-Therapeutics-Announces-Topline-Results-of-PARADIGM-Phase-3-Proof-of-Concept-Trial-of-Solriamfetol-in-Major-Depressive-Disorder-MDD-with-and-without-Excessive-Daytime-Sleepin.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","AXSM","BK4597","CNS","PACI.U","BK4585","BK4215","BK4505","ADHD","BK4135","ABVC","ESS","BK4139"],"gpt_icon":0},{"id":"2523949576","title":"Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2523949576","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523949576?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:31","pubTimestamp":1743424260,"startTime":"0","endTime":"0","summary":"Policy update increases access for millions covered by Evernorth Health ServicesMALVERN, Pa., March  31, 2025  (GLOBE NEWSWIRE) -- Neuronetics,Inc. (NASDAQ: STIM), a vertically integrated, commercial ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052299/0/en/Evernorth-Health-Services-a-Cigna-Company-Expands-NeuroStar-TMS-Coverage-for-Adolescents-Struggling-with-Depression.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STIM","BK4139","ABVC","BK4082"],"gpt_icon":0},{"id":"2522416355","title":"Press Release: Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2522416355","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522416355?lang=en_us&edition=fundamental","pubTime":"2025-03-27 05:00","pubTimestamp":1743022800,"startTime":"0","endTime":"0","summary":"Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved. In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025. $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission. \"The capital raised over the past year has allowed us to strengthen our balance sheet and complete all required clinical trials for NDA submission for CTx-1301. We look forward to meeting with the FDA next week, submitting our new drug application this summer, and, assuming approval by the FDA, bringing to market the first, true, once-daily stimulant medication to treat ADHD over the entire active day,\" said Cingulate Chairman and CEO Shane J Schaffer.and adolescent studies -- a fixed dose study and a dose optimization. treatment emergent adverse events and confirming that the safety profile. and pediatric safety data will be prepared and included i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","CING","BK4555","BK4588","BK4604","ABVC","BK4139","BK4099","BK4585","BK4007","03160"],"gpt_icon":0},{"id":"2522845871","title":"Buy Rating Affirmed for Axsome Therapeutics Amid Promising ADHD Treatment Results and Strategic Market Positioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2522845871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522845871?lang=en_us&edition=fundamental","pubTime":"2025-03-26 16:35","pubTimestamp":1742978128,"startTime":"0","endTime":"0","summary":"Analyst Jason Gerberry from Bank of America Securities maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) and increased the pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-axsome-therapeutics-amid-promising-adhd-treatment-results-and-strategic-market-positioning?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-axsome-therapeutics-amid-promising-adhd-treatment-results-and-strategic-market-positioning?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADHD","AXSM","ABVC"],"gpt_icon":0},{"id":"2522021437","title":"Axsome Therapeutics' Phase 3 Trial of Solriamfetol to Treat ADHD Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2522021437","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522021437?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:45","pubTimestamp":1742903124,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics  said Tuesday that the phase 3 trial of solriamfetol as a potential treatment for attention deficit hyperactivity disorder achieved its primary and key secondary endpoints, demonstrating \"statistically significant\" improvement in symptoms and disease severity.The study met its primary endpoint of a statistically significant reduction in the Adult ADHD Investigator Symptom Rating Scale compared with placebo at week six. The study also achieved the key secondary endpoint of a significant reduction in overall ADHD disease severity, Axsome added.Solriamfetol was also well-tolerated in the study, with no serious adverse events reported, according to Axsome.Axsome Chief Executive Officer Herriot Tabuteau said the company plans to start a solriamfetol trial in pediatric patients this year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","AXSM","BK4505","ABVC","BK4139","ADHD","BK4585"],"gpt_icon":0},{"id":"2521499351","title":"Press Release: Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2521499351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521499351?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:10","pubTimestamp":1742501400,"startTime":"0","endTime":"0","summary":"-- Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 --. -- Completed enrollment in ALTO-203 Phase 2 proof-of-concept MDD trial; on track to report topline data in the second quarter of 2025 --. -- Novel transdermal formulation of ALTO-101 demonstrated greater drug exposure and improved tolerability profile; topline data from Phase 2 trial of ALTO-101 in schizophrenia expected in the second half of 2025 --. -- Company's precision psychiatry approach underpins recently granted patents covering the use of ALTO-100 and ALTO-300 in biomarker defined populations --. -- Strong cash position of approximately $169 million expected to fund planned operations into 2028, and through at least four upcoming clinical study readouts --. Alto Neuroscience, Inc.   a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the ful","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC","ANRO","BK4007"],"gpt_icon":0},{"id":"2520742445","title":"We Are Turning Too Many People into Medical Patients -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2520742445","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520742445?lang=en_us&edition=fundamental","pubTime":"2025-03-18 00:08","pubTimestamp":1742227680,"startTime":"0","endTime":"0","summary":"When I meet a patient with a complicated medical history, I often start by asking when they were last perfectly well. Darcie couldn't remember ever being truly well.Darcie is 20 years old. She was referred to me because she was having regular seizures, but her illness began long before. It began with headaches as a child, which a neurologist diagnosed as migraine when she was 13. By the time she reached my office, her referral letter included hypermobile Ehlers Danlos syndrome , anorexia, irritable bowel syndrome, postural orthostatic tachycardia syndrome , autism, ADHD, depression and anxiety. She had also started having seizures every day, which was why she was in my clinic.Darcie was clearly sick. She had barely been out of her own home for a year. Yet I came to believe that most of her symptoms, including her seizures and faints, were psychosomatic.Take Darcie's diagnosis of PoTS, a condition in which changes in posture provoke a fall in blood pressure that can cause fainting or di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"gpt_icon":0},{"id":"2519633827","title":"Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519633827","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519633827?lang=en_us&edition=fundamental","pubTime":"2025-03-14 22:55","pubTimestamp":1741964100,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics’ AXSM Auvelity  was launched in the United States in 2022 for the treatment of major depressive disorder , making it the first approved drug in the company’s portfolio.Auvelity generated sales worth $291.4 million in 2024, reflecting an increase of 124% year over year in the United States. Sales of the drug are being driven by an increase in unit sales volume and the momentum is likely to continue in 2025.Axsome is also working to expand the label of Auvelity for the larger commercial opportunity in other central nervous system  disorders like Alzheimer’s disease  agitation and smoking cessation.The successful development and potential approval of Auvelity in additional indications will help the drug address a broader patient population and drive sales further.Axsome is evaluating Sunosi in separate phase III studies for treating attention deficit hyperactivity disorder , MDD, binge eating disorder and excessive sleepiness associated with shift work disorder.Top-lin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/auvelity-other-drugs-aid-axsms-145500596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171311.SGD","BK4007","LU2065171402.SGD","JAZZ","LU0109394709.USD","AXSM","LU2065169927.USD","BK4533","BK4532","LU0889565916.HKD","LU0320765992.SGD","IE00BN0W2W23.USD","BK4585","ACAD","LU0823416689.USD","BK4139","ADHD","BK4135","BK4505","CNS","ABVC","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2065170008.USD"],"gpt_icon":0},{"id":"2518782331","title":"Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2518782331","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518782331?lang=en_us&edition=fundamental","pubTime":"2025-03-11 06:57","pubTimestamp":1741647420,"startTime":"0","endTime":"0","summary":"STOUGHTON, Mass., March  10, 2025  (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3040237/34897/en/Collegium-Announces-Poster-Presentations-at-the-2025-National-Association-of-Pediatric-Nurse-Practitioners-National-Conference-on-Pediatric-Health-Care.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4223","DEA","NHLD","ADHD","BK4135","BK4023","CII","BK4139","BK4194","BK4585","ABVC","HCP","BK4588","CNS"],"gpt_icon":0},{"id":"2517651964","title":"BRIEF-ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517651964","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517651964?lang=en_us&edition=fundamental","pubTime":"2025-03-08 05:21","pubTimestamp":1741382514,"startTime":"0","endTime":"0","summary":"BRIEF-ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc BiopharmaMarch 7  - ABVC Biopharma Inc ABVC.O:ABVC BIOPHARMA INC - ON MARCH 5, LEEDS CHOW RESIGNS AS CFO OF ABVC BIOPHARMAABVC BIOPHARMA INC - CEO UTTAM PATIL TO SERVE AS INTERIM CFO OF ABVC BIOPHARMAFurther company coverage: ABVC.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ0RK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"gpt_icon":0},{"id":"2517538457","title":"JNJ Halts Development of Depression Drug Over Efficacy Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2517538457","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517538457?lang=en_us&edition=fundamental","pubTime":"2025-03-08 01:45","pubTimestamp":1741369500,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ decided to discontinue the Phase 3 VENTURA development program, which is evaluating aticaprant as an adjunctive treatment for major depressive disorder .Though data from the VENTURA program did confirm that the J&J drug was safe and well-tolerated in study participants, the decision to stop developing it for MDD indication is due to ‘insufficient efficacy in the target patient population.’ However, the pharma giant still intends to explore aticaprant’s potential ‘in other areas of high unmet need.’。J&J is currently undergoing full analyses of data from the VENTURA program and intends to share the same at a future medical meeting.This comes as a setback to J&J, which had high expectations for aticaprant in the MDD indication. The company has forecasted generating annual peak sales in the range of $1-$5 billion from the drug in the now-abandoned indication.J&J Reiterates Long-Term View for Innovative Medicine Biz","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jnj-halts-development-depression-drug-174500525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0098860793.USD","LU0122379950.USD","IE00BJJMRZ35.SGD","LU0795875086.SGD","LU0234570918.USD","BK4581","LU0889566641.SGD","LU2468319806.SGD","LU2505996681.GBP","LU1059921491.USD","SG9999001440.SGD","BK4532","IE00BFTCPJ56.SGD","LU0289739699.SGD","JNJ","LU1732799900.SGD","ITCI","LU0912757837.SGD","IE00B1BXHZ80.USD","IE0002270589.USD","LU1057294990.SGD","ABVC","LU2129689514.USD","IE00BGHQF631.EUR","LU0345769631.USD","BK4533","LU1261432733.SGD","LU1267930813.SGD","LU1066051225.USD","IE0002141913.USD","LU2602419157.SGD","LU2112291526.USD","LU1732800096.USD","LU0792757196.USD","SG9999002224.SGD","IE00BSNM7G36.USD","IE00BVYPNV92.GBP","IE00B19Z3B42.SGD","NMRA","LU2430703178.SGD","IE00B19Z3581.USD","IE000M9KFDE8.USD","LU1061106388.HKD","LU0058720904.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1674673691.USD","LU1066051498.USD","IE00BDGV0183.EUR","LU0234572021.USD"],"gpt_icon":0},{"id":"2517191949","title":"AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2517191949","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517191949?lang=en_us&edition=fundamental","pubTime":"2025-03-06 23:27","pubTimestamp":1741274820,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi .The settlement agreement resolves the patent litigation brought by Axsome on Hikma for submitting an abbreviated new drug application to the FDA, seeking marketing approval for a generic version of Sunosi in the United States. The patent litigation is pending in the United States District Court for the District of New Jersey.Axsome acquired U.S. rights to Sunosi from Jazz Pharmaceuticals JAZZ in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.Jazz had received approval for Sunosi as a treatment for narcolepsy in 2019.JAZZ is entitled to receive a high single-digit royalty from Axsome on net sales of Sunosi in the United States. AXSM out-licensed its ex-U.S. marketing rights of Sunosi to Pharmanovia in February 2023.In the past year, shares of Axsome have ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/axsm-settles-sunosi-patent-litigation-152700923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AXSM","LU0823416689.USD","ABVC","IE00BN0W2V16.EUR","BK4139","IE00BN0W2W23.USD","RIGL","BK4585","BK4533","ADHD","BK4532","IE00BN0W2T93.GBP","LU0109394709.USD","BK4007","BK4505","JAZZ","ANIP","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2517215640","title":"MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517215640","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517215640?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:00","pubTimestamp":1741262400,"startTime":"0","endTime":"0","summary":"--First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet  in Generalized Anxiety Disorder ; 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama--. --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder  in 1H of 2025--. --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD--. --Company to host a conference call today at 8:00 a.m. EST--. NEW YORK, March 06, 2025----Mind Medicine  Inc. , , a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its fourth quarter and full year 2024 financial results and provided an update on business highlights.Initiated dosing i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-reports-fourth-quarter-full-120000302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4547","LU0256331488.USD","MNMD","BK4139","BK4588","BK4007","BK4585","BK4213","ODT","APA","ABVC"],"gpt_icon":0},{"id":"2517921713","title":"ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921713","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921713?lang=en_us&edition=fundamental","pubTime":"2025-03-06 05:01","pubTimestamp":1741208460,"startTime":"0","endTime":"0","summary":"ABVC plans to allocate significant resources toward constructing \"gigafactories\" in the U.S., for its products. The initial phase of such development represents an estimated investment of USD 120 million. The factories are expected to be built to enable the use of cutting-edge technologies- including vertical farming, hydroponic systems, and AI-driven environmental controls- to cultivate high-value medicinal plants under controlled, pesticide-free conditions. Initially, the goal is to achieve an annual output of over 1,000 metric tons of botanical raw materials, as we plan to design the facility to reduce raw material costs by 30%, enhance product quality, and provide a sustainable, traceable supply chain to support ABVC's botanical-based pharmaceuticals. Together, these projects are expected to significantly expand ABVC's drug manufacturing capacity, create more than 500 new jobs across research, manufacturing and quality control operations, and support projected product sales exceedi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abvc-biopharma-plans-expand-investment-210100299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ABVC","R","BK4232","BK4022"],"gpt_icon":1},{"id":"2517408119","title":"NetraMark Showcases AI Breakthroughs in Clinical Trials for MDD and Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2517408119","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517408119?lang=en_us&edition=fundamental","pubTime":"2025-03-06 01:45","pubTimestamp":1741196753,"startTime":"0","endTime":"0","summary":"An update from NetraMark Holdings ( ($TSE:AIAI) ) is now available. NetraMark Holdings Inc. presented groundbreaking studies at the ISCTM conferenc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/netramark-showcases-ai-breakthroughs-in-clinical-trials-for-mdd-and-schizophrenia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/netramark-showcases-ai-breakthroughs-in-clinical-trials-for-mdd-and-schizophrenia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2516521674","title":"Cingulate reports safety results from final Phase 3 trials for CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2516521674","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516521674?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:07","pubTimestamp":1741097232,"startTime":"0","endTime":"0","summary":"Cingulate (CING) released Phase 3 safety data for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD. The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cingulate-reports-safety-results-from-final-phase-3-trials-for-ctx-1301?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cingulate-reports-safety-results-from-final-phase-3-trials-for-ctx-1301?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CING","BK4007","ABVC"],"gpt_icon":0},{"id":"2516674892","title":"Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674892","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674892?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":"Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY, Kan.,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036578/0/en/Cingulate-Reports-Safety-Results-from-Final-Phase-3-Trials-for-Lead-ADHD-Asset-CTx-1301-On-Track-to-File-for-FDA-Approval-Mid-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4551","BK4139","CING","ADHD","BK4503","API","BK4535","ABVC","BK4007"],"gpt_icon":0},{"id":"2516675847","title":"Strategic Adjustments and MDD Focus Drive Buy Rating for Neumora Therapeutics Amid Study Delays","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675847?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:35","pubTimestamp":1741091742,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-adjustments-and-mdd-focus-drive-buy-rating-for-neumora-therapeutics-amid-study-delays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-adjustments-and-mdd-focus-drive-buy-rating-for-neumora-therapeutics-amid-study-delays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","NMRA","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":75,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABVC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-30","symbol":"ABVC","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745985600000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2025-04-15","symbol":"ABVC","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1744689600000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2024-11-14","symbol":"ABVC","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.02},{"market":"US","date":"2024-08-14","symbol":"ABVC","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"","actualEps":-0.09},{"market":"US","date":"2024-05-17","symbol":"ABVC","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715918400000,"reportTimeType":"post","actualEps":-0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABVC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ABVC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ABVC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ABVC","date":"2025-08-01","current":-13.399375,"percent":0.151909,"low":-26.463766,"twenty":-11.220378,"median":-1.612414,"eighty":-0.794757,"high":-0.260274,"avg":-5.529761,"sd":5.973523,"marketCap":39002284},"quantilePoints":[{"date":"2020-08-07","current":-17.817247,"twenty":-104.984049,"median":-60.422571,"eighty":-15.816469,"marketCap":73008719},{"date":"2020-08-14","current":-14.118204,"twenty":-104.984049,"median":-58.912006,"eighty":-15.816469,"marketCap":76088142},{"date":"2020-08-21","current":-14.296916,"twenty":-104.984049,"median":-47.962314,"eighty":-15.601069,"marketCap":77051284},{"date":"2020-08-28","current":-12.867224,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":69346155},{"date":"2020-09-04","current":-14.296916,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":77051284},{"date":"2020-09-11","current":-14.118204,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":76088142},{"date":"2020-09-18","current":-14.296916,"twenty":-104.984049,"median":-47.962314,"eighty":-15.563236,"marketCap":77051284},{"date":"2020-09-25","current":-14.118204,"twenty":-104.984049,"median":-47.962314,"eighty":-15.299453,"marketCap":76088142},{"date":"2020-10-02","current":-14.654339,"twenty":-104.984049,"median":-47.962314,"eighty":-14.943492,"marketCap":78977566},{"date":"2020-10-09","current":-14.887513,"twenty":-104.984049,"median":-47.962314,"eighty":-14.873601,"marketCap":80234224},{"date":"2020-10-16","current":-15.910707,"twenty":-104.984049,"median":-47.962314,"eighty":-14.887513,"marketCap":85748593},{"date":"2020-10-23","current":-15.522641,"twenty":-104.984049,"median":-47.962314,"eighty":-14.957404,"marketCap":83657164},{"date":"2020-10-30","current":-15.134575,"twenty":-104.984049,"median":-46.033619,"eighty":-15.082344,"marketCap":81565734},{"date":"2020-11-06","current":-15.199238,"twenty":-104.984049,"median":-46.033619,"eighty":-15.134575,"marketCap":81914224},{"date":"2020-11-13","current":-15.009247,"twenty":-104.984049,"median":-43.698955,"eighty":-14.957404,"marketCap":80890296},{"date":"2020-11-20","current":-13.64563,"twenty":-104.984049,"median":-39.895803,"eighty":-14.839343,"marketCap":82154224},{"date":"2020-11-27","current":-14.327911,"twenty":-104.984049,"median":-39.895803,"eighty":-14.654339,"marketCap":86261935},{"date":"2020-12-04","current":-14.498482,"twenty":-104.984049,"median":-39.895803,"eighty":-14.484769,"marketCap":87288863},{"date":"2020-12-11","current":-15.351334,"twenty":-104.984049,"median":-38.369814,"eighty":-14.475627,"marketCap":92423502},{"date":"2020-12-18","current":-17.057037,"twenty":-104.984049,"median":-37.594122,"eighty":-14.484769,"marketCap":102692780},{"date":"2020-12-24","current":-17.739319,"twenty":-104.984049,"median":-36.826895,"eighty":-14.498482,"marketCap":106800491},{"date":"2020-12-31","current":-17.398178,"twenty":-104.984049,"median":-36.826895,"eighty":-14.498482,"marketCap":104746635},{"date":"2021-01-08","current":-20.052297,"twenty":-104.984049,"median":-36.67345,"eighty":-14.549617,"marketCap":120725895},{"date":"2021-01-15","current":-21.65648,"twenty":-104.984049,"median":-34.580924,"eighty":-14.654339,"marketCap":130383966},{"date":"2021-01-22","current":-21.255434,"twenty":-104.984049,"median":-33.757987,"eighty":-14.654339,"marketCap":127969448},{"date":"2021-01-29","current":-20.052297,"twenty":-104.984049,"median":-33.757987,"eighty":-14.666109,"marketCap":120725895},{"date":"2021-02-05","current":-19.851774,"twenty":-104.984049,"median":-33.757987,"eighty":-14.751318,"marketCap":119518636},{"date":"2021-02-12","current":-19.450728,"twenty":-104.984049,"median":-32.897231,"eighty":-14.809783,"marketCap":117104118},{"date":"2021-02-19","current":-20.052297,"twenty":-104.984049,"median":-32.897231,"eighty":-14.839343,"marketCap":120725895},{"date":"2021-02-26","current":-17.646021,"twenty":-104.984049,"median":-32.530424,"eighty":-14.873601,"marketCap":106238787},{"date":"2021-03-05","current":-17.646021,"twenty":-104.984049,"median":-31.609752,"eighty":-14.887513,"marketCap":106238787},{"date":"2021-03-12","current":-18.047067,"twenty":-104.984049,"median":-30.689079,"eighty":-14.920184,"marketCap":108653305},{"date":"2021-03-19","current":-10.850476,"twenty":-104.984049,"median":-30.689079,"eighty":-14.839343,"marketCap":106238787},{"date":"2021-03-26","current":-10.973777,"twenty":-104.984049,"median":-30.437981,"eighty":-14.654339,"marketCap":107446046},{"date":"2021-04-01","current":-11.097077,"twenty":-104.984049,"median":-30.103498,"eighty":-14.498482,"marketCap":108653305},{"date":"2021-04-09","current":-10.850476,"twenty":-104.984049,"median":-30.103498,"eighty":-14.386997,"marketCap":106238787},{"date":"2021-04-16","current":-10.850476,"twenty":-104.984049,"median":-29.613533,"eighty":-14.327911,"marketCap":106238787},{"date":"2021-04-23","current":-11.097077,"twenty":-104.984049,"median":-28.765565,"eighty":-14.296916,"marketCap":108653305},{"date":"2021-04-30","current":-11.097077,"twenty":-104.984049,"median":-28.224507,"eighty":-14.296916,"marketCap":108653305},{"date":"2021-05-07","current":-11.46698,"twenty":-104.984049,"median":-28.224507,"eighty":-14.296916,"marketCap":112275082},{"date":"2021-05-14","current":-13.730013,"twenty":-104.984049,"median":-27.28369,"eighty":-14.296916,"marketCap":132798484},{"date":"2021-05-21","current":-13.730013,"twenty":-104.984049,"median":-26.65832,"eighty":-14.296916,"marketCap":132798484},{"date":"2021-05-28","current":-13.730013,"twenty":-103.326706,"median":-26.132665,"eighty":-14.118204,"marketCap":132798484},{"date":"2021-06-04","current":-13.355558,"twenty":-100.840692,"median":-25.838836,"eighty":-14.118204,"marketCap":129176707},{"date":"2021-06-11","current":-12.981103,"twenty":-100.840692,"median":-25.62158,"eighty":-14.066248,"marketCap":125554930},{"date":"2021-06-18","current":-11.857738,"twenty":-100.840692,"median":-25.489795,"eighty":-14.066248,"marketCap":114689600},{"date":"2021-06-25","current":-12.48183,"twenty":-100.840692,"median":-23.923098,"eighty":-13.947524,"marketCap":120725895},{"date":"2021-07-02","current":-11.233647,"twenty":-100.840692,"median":-23.282,"eighty":-13.770344,"marketCap":108653305},{"date":"2021-07-09","current":-12.48183,"twenty":-100.840692,"median":-22.944579,"eighty":-13.730013,"marketCap":120725895},{"date":"2021-07-16","current":-12.48183,"twenty":-100.840692,"median":-22.775869,"eighty":-13.730013,"marketCap":120725895},{"date":"2021-07-23","current":-12.357012,"twenty":-100.840692,"median":-22.633127,"eighty":-13.64563,"marketCap":119518636},{"date":"2021-07-30","current":-12.357585,"twenty":-100.840692,"median":-22.438449,"eighty":-13.64563,"marketCap":119524184},{"date":"2021-08-06","current":-8.290388,"twenty":-100.840692,"median":-22.020758,"eighty":-13.355558,"marketCap":80185717},{"date":"2021-08-13","current":-5.99167,"twenty":-100.840692,"median":-21.65648,"eighty":-13.337149,"marketCap":58684815},{"date":"2021-08-20","current":-5.242711,"twenty":-100.840692,"median":-21.054911,"eighty":-13.23074,"marketCap":51349213},{"date":"2021-08-27","current":-7.670371,"twenty":-100.840692,"median":-20.611957,"eighty":-13.105921,"marketCap":75126681},{"date":"2021-09-03","current":-8.393504,"twenty":-100.840692,"median":-20.536178,"eighty":-12.981103,"marketCap":82209331},{"date":"2021-09-10","current":-8.290199,"twenty":-100.840692,"median":-20.327641,"eighty":-12.731467,"marketCap":81197524},{"date":"2021-09-17","current":-7.386283,"twenty":-100.840692,"median":-20.25282,"eighty":-12.48183,"marketCap":72344211},{"date":"2021-09-24","current":-6.404889,"twenty":-100.840692,"median":-20.249018,"eighty":-12.48183,"marketCap":62732043},{"date":"2021-10-01","current":-5.862539,"twenty":-100.840692,"median":-20.143991,"eighty":-12.48183,"marketCap":57420056},{"date":"2021-10-08","current":-5.578452,"twenty":-96.807064,"median":-20.052297,"eighty":-12.48183,"marketCap":54637586},{"date":"2021-10-15","current":-6.998891,"twenty":-95.798657,"median":-20.052297,"eighty":-12.48183,"marketCap":68549935},{"date":"2021-10-22","current":-6.379063,"twenty":-95.798657,"median":-20.02901,"eighty":-12.357012,"marketCap":62479092},{"date":"2021-10-29","current":-6.885086,"twenty":-95.798657,"median":-20.005723,"eighty":-12.332048,"marketCap":67435282},{"date":"2021-11-05","current":-10.164989,"twenty":-93.770452,"median":-19.95676,"eighty":-12.112235,"marketCap":99559965},{"date":"2021-11-12","current":-8.999403,"twenty":-93.263401,"median":-19.851774,"eighty":-11.72383,"marketCap":88143755},{"date":"2021-11-19","current":-9.556177,"twenty":-93.263401,"median":-19.851774,"eighty":-11.230993,"marketCap":93218994},{"date":"2021-11-26","current":-9.294762,"twenty":-93.263401,"median":-19.851774,"eighty":-11.139591,"marketCap":90668931},{"date":"2021-12-03","current":-8.510516,"twenty":-93.263401,"median":-19.450728,"eighty":-11.097077,"marketCap":83018740},{"date":"2021-12-10","current":-10.108053,"twenty":-90.465498,"median":-19.450728,"eighty":-11.097077,"marketCap":98602462},{"date":"2021-12-17","current":-10.398515,"twenty":-88.60023,"median":-19.450728,"eighty":-11.097077,"marketCap":101435866},{"date":"2021-12-23","current":-10.950391,"twenty":-88.60023,"median":-19.250205,"eighty":-11.042884,"marketCap":106819334},{"date":"2021-12-31","current":-9.846638,"twenty":-88.60023,"median":-18.803806,"eighty":-10.973777,"marketCap":96052398},{"date":"2022-01-07","current":-9.90473,"twenty":-88.60023,"median":-18.754997,"eighty":-10.850476,"marketCap":96619079},{"date":"2022-01-14","current":-9.556177,"twenty":-88.60023,"median":-18.687731,"eighty":-10.850476,"marketCap":93218994},{"date":"2022-01-21","current":-7.900547,"twenty":-88.60023,"median":-18.539338,"eighty":-10.850476,"marketCap":77068591},{"date":"2022-01-28","current":-7.174394,"twenty":-88.60023,"median":-18.52056,"eighty":-10.712213,"marketCap":69985081},{"date":"2022-02-04","current":-7.319625,"twenty":-88.60023,"median":-18.401426,"eighty":-10.554554,"marketCap":71401783},{"date":"2022-02-11","current":-7.668178,"twenty":-88.60023,"median":-18.286122,"eighty":-10.404324,"marketCap":74801868},{"date":"2022-02-18","current":-7.348671,"twenty":-88.60023,"median":-18.220695,"eighty":-10.343792,"marketCap":71685123},{"date":"2022-02-25","current":-7.116302,"twenty":-88.60023,"median":-18.188702,"eighty":-10.164989,"marketCap":69418400},{"date":"2022-03-04","current":-7.116302,"twenty":-88.60023,"median":-18.047067,"eighty":-9.98737,"marketCap":69418400},{"date":"2022-03-11","current":-6.622518,"twenty":-88.60023,"median":-18.047067,"eighty":-9.875684,"marketCap":64601613},{"date":"2022-03-18","current":-6.564425,"twenty":-88.60023,"median":-17.909889,"eighty":-9.788546,"marketCap":64034932},{"date":"2022-03-25","current":-7.029163,"twenty":-88.60023,"median":-17.850261,"eighty":-9.704796,"marketCap":68568379},{"date":"2022-04-01","current":-6.339112,"twenty":-88.60023,"median":-17.739319,"eighty":-9.704796,"marketCap":81386671},{"date":"2022-04-08","current":-6.31572,"twenty":-88.60023,"median":-17.732346,"eighty":-9.704796,"marketCap":81086351},{"date":"2022-04-14","current":-5.894672,"twenty":-88.60023,"median":-17.680293,"eighty":-9.60846,"marketCap":75680594},{"date":"2022-04-22","current":-5.754323,"twenty":-88.60023,"median":-17.646021,"eighty":-9.54452,"marketCap":73878675},{"date":"2022-04-29","current":-5.590582,"twenty":-88.60023,"median":-17.646021,"eighty":-9.360688,"marketCap":71776436},{"date":"2022-05-06","current":-5.766019,"twenty":-88.60023,"median":-17.646021,"eighty":-9.252091,"marketCap":74028835},{"date":"2022-05-13","current":-5.2631,"twenty":-88.60023,"median":-17.58281,"eighty":-9.119715,"marketCap":67571959},{"date":"2022-05-20","current":-3.799171,"twenty":-88.60023,"median":-17.545855,"eighty":-9.098246,"marketCap":67267162},{"date":"2022-05-27","current":-3.527801,"twenty":-88.60023,"median":-17.467267,"eighty":-9.097299,"marketCap":62462364},{"date":"2022-06-03","current":-3.744897,"twenty":-88.60023,"median":-17.373275,"eighty":-9.093511,"marketCap":66306202},{"date":"2022-06-10","current":-1.628216,"twenty":-88.60023,"median":-17.227608,"eighty":-8.989743,"marketCap":28828783},{"date":"2022-06-17","current":-1.764263,"twenty":-88.60023,"median":-17.146548,"eighty":-8.906096,"marketCap":31237588},{"date":"2022-06-24","current":-1.790857,"twenty":-88.60023,"median":-17.057037,"eighty":-8.85907,"marketCap":31708458},{"date":"2022-07-01","current":-1.82722,"twenty":-88.60023,"median":-17.057037,"eighty":-8.794971,"marketCap":32352301},{"date":"2022-07-08","current":-1.881494,"twenty":-88.60023,"median":-16.871014,"eighty":-8.794971,"marketCap":33313261},{"date":"2022-07-15","current":-1.415282,"twenty":-88.60023,"median":-16.641799,"eighty":-8.791309,"marketCap":25058619},{"date":"2022-07-22","current":-1.4189,"twenty":-88.60023,"median":-16.368319,"eighty":-8.790393,"marketCap":25122683},{"date":"2022-07-29","current":-1.175934,"twenty":-88.60023,"median":-16.201757,"eighty":-8.70552,"marketCap":20820788},{"date":"2022-08-05","current":-1.14735,"twenty":-88.60023,"median":-16.10474,"eighty":-8.638835,"marketCap":20314682},{"date":"2022-08-12","current":-1.212116,"twenty":-88.60023,"median":-15.910707,"eighty":-8.55118,"marketCap":21461427},{"date":"2022-08-19","current":-1.600085,"twenty":-88.60023,"median":-15.82702,"eighty":-8.491696,"marketCap":28150574},{"date":"2022-08-26","current":-1.546748,"twenty":-88.60023,"median":-15.82702,"eighty":-8.487276,"marketCap":27212221},{"date":"2022-09-02","current":-1.875961,"twenty":-88.60023,"median":-15.82702,"eighty":-8.487276,"marketCap":33004121},{"date":"2022-09-09","current":-2.023095,"twenty":-88.60023,"median":-15.82702,"eighty":-8.340059,"marketCap":35592680},{"date":"2022-09-16","current":-1.3426,"twenty":-88.60023,"median":-15.800641,"eighty":-8.303464,"marketCap":23620596},{"date":"2022-09-23","current":-1.680089,"twenty":-88.60023,"median":-15.762085,"eighty":-8.21272,"marketCap":29558103},{"date":"2022-09-30","current":-1.618476,"twenty":-88.60023,"median":-15.716674,"eighty":-8.036784,"marketCap":28474144},{"date":"2022-10-07","current":-1.626753,"twenty":-88.60023,"median":-15.610527,"eighty":-7.747849,"marketCap":28619750},{"date":"2022-10-14","current":-1.287424,"twenty":-88.60023,"median":-15.563236,"eighty":-7.670371,"marketCap":22649887},{"date":"2022-10-21","current":-1.324208,"twenty":-88.60023,"median":-15.563236,"eighty":-7.581872,"marketCap":23297027},{"date":"2022-10-28","current":-1.359888,"twenty":-88.60023,"median":-15.563236,"eighty":-7.479591,"marketCap":23924752},{"date":"2022-11-04","current":-1.348301,"twenty":-88.60023,"median":-15.563236,"eighty":-7.430234,"marketCap":23720903},{"date":"2022-11-11","current":-1.327151,"twenty":-88.60023,"median":-15.563236,"eighty":-7.386283,"marketCap":23348798},{"date":"2022-11-18","current":-1.231758,"twenty":-88.60023,"median":-15.563236,"eighty":-7.319625,"marketCap":24008880},{"date":"2022-11-25","current":-1.245038,"twenty":-88.60023,"median":-15.522641,"eighty":-7.302197,"marketCap":24267736},{"date":"2022-12-02","current":-1.269773,"twenty":-88.60023,"median":-15.497757,"eighty":-7.288183,"marketCap":24749855},{"date":"2022-12-09","current":-1.228438,"twenty":-88.60023,"median":-15.445794,"eighty":-7.272153,"marketCap":23944166},{"date":"2022-12-16","current":-1.162036,"twenty":-88.60023,"median":-15.329372,"eighty":-7.261532,"marketCap":22649887},{"date":"2022-12-23","current":-1.145435,"twenty":-88.60023,"median":-15.299453,"eighty":-7.226677,"marketCap":22326317},{"date":"2022-12-30","current":-1.037532,"twenty":-88.60023,"median":-15.199238,"eighty":-7.174394,"marketCap":20223113},{"date":"2023-01-06","current":-1.512141,"twenty":-88.133914,"median":-15.199238,"eighty":-7.100329,"marketCap":29473974},{"date":"2023-01-13","current":-1.435777,"twenty":-86.576754,"median":-15.134575,"eighty":-6.953369,"marketCap":27985521},{"date":"2023-01-20","current":-1.29484,"twenty":-85.538648,"median":-15.003998,"eighty":-6.821454,"marketCap":25238445},{"date":"2023-01-27","current":-1.261473,"twenty":-85.538648,"median":-14.852734,"eighty":-6.739858,"marketCap":24588070},{"date":"2023-02-03","current":-1.167182,"twenty":-85.538648,"median":-14.654339,"eighty":-6.646897,"marketCap":22750194},{"date":"2023-02-10","current":-1.245038,"twenty":-70.569383,"median":-14.475627,"eighty":-6.564425,"marketCap":24267736},{"date":"2023-02-17","current":-1.203539,"twenty":-70.569383,"median":-14.327911,"eighty":-6.471848,"marketCap":23458844},{"date":"2023-02-24","current":-1.161758,"twenty":-70.569383,"median":-14.296916,"eighty":-6.418638,"marketCap":22644477},{"date":"2023-03-03","current":-1.170116,"twenty":-70.569383,"median":-14.296916,"eighty":-6.368733,"marketCap":22807387},{"date":"2023-03-10","current":-0.98808,"twenty":-70.569383,"median":-14.296916,"eighty":-6.32741,"marketCap":19259209},{"date":"2023-03-17","current":-1.002957,"twenty":-70.569383,"median":-14.296916,"eighty":-6.222154,"marketCap":19549189},{"date":"2023-03-24","current":-1.019673,"twenty":-70.569383,"median":-14.118204,"eighty":-6.090777,"marketCap":19875009},{"date":"2023-03-31","current":-1.069821,"twenty":-70.569383,"median":-14.118204,"eighty":-5.965645,"marketCap":20852468},{"date":"2023-04-06","current":-1.043077,"twenty":-70.569383,"median":-14.066248,"eighty":-5.910288,"marketCap":20331189},{"date":"2023-04-14","current":-1.321345,"twenty":-64.954263,"median":-14.066248,"eighty":-5.744966,"marketCap":21700767},{"date":"2023-04-21","current":-1.310948,"twenty":-60.422571,"median":-13.83181,"eighty":-5.658826,"marketCap":21530015},{"date":"2023-04-28","current":-1.398249,"twenty":-47.962314,"median":-13.730013,"eighty":-5.59802,"marketCap":22963775},{"date":"2023-05-05","current":-1.498124,"twenty":-47.962314,"median":-13.705049,"eighty":-5.49939,"marketCap":24604044},{"date":"2023-05-12","current":-1.558049,"twenty":-47.962314,"median":-13.64563,"eighty":-5.24151,"marketCap":25588206},{"date":"2023-05-19","current":-1.963531,"twenty":-47.962314,"median":-13.355558,"eighty":-3.791935,"marketCap":24056194},{"date":"2023-05-26","current":-1.809834,"twenty":-47.962314,"median":-13.299333,"eighty":-3.683387,"marketCap":22173165},{"date":"2023-06-02","current":-1.797516,"twenty":-46.033619,"median":-13.23074,"eighty":-3.614639,"marketCap":22022260},{"date":"2023-06-09","current":-1.684251,"twenty":-43.485789,"median":-12.981103,"eighty":-3.299851,"marketCap":20634592},{"date":"2023-06-16","current":-1.609276,"twenty":-39.895803,"median":-12.731467,"eighty":-2.015739,"marketCap":19716041},{"date":"2023-06-23","current":-1.446742,"twenty":-38.369814,"median":-12.48183,"eighty":-1.965287,"marketCap":17724753},{"date":"2023-06-30","current":-1.344455,"twenty":-36.826895,"median":-12.48183,"eighty":-1.921295,"marketCap":16471587},{"date":"2023-07-07","current":-1.241901,"twenty":-36.397248,"median":-12.48183,"eighty":-1.877068,"marketCap":15215141},{"date":"2023-07-14","current":-1.204949,"twenty":-33.757987,"median":-12.48183,"eighty":-1.845821,"marketCap":14762426},{"date":"2023-07-21","current":-1.017513,"twenty":-33.635231,"median":-12.357585,"eighty":-1.824236,"marketCap":12466049},{"date":"2023-07-28","current":-0.905985,"twenty":-32.837315,"median":-12.357012,"eighty":-1.794379,"marketCap":11099674},{"date":"2023-08-04","current":-0.900255,"twenty":-31.425617,"median":-11.857738,"eighty":-1.773608,"marketCap":11029470},{"date":"2023-08-11","current":-0.63419,"twenty":-30.638859,"median":-11.386083,"eighty":-1.73785,"marketCap":7769771},{"date":"2023-08-18","current":-0.55807,"twenty":-30.103498,"median":-11.220378,"eighty":-1.68709,"marketCap":7062935},{"date":"2023-08-25","current":-0.523965,"twenty":-29.033151,"median":-11.097077,"eighty":-1.675707,"marketCap":6631311},{"date":"2023-09-01","current":-0.420938,"twenty":-28.224507,"median":-11.097077,"eighty":-1.659207,"marketCap":5327390},{"date":"2023-09-08","current":-0.350246,"twenty":-27.178685,"median":-11.097077,"eighty":-1.647519,"marketCap":4432713},{"date":"2023-09-15","current":-0.343819,"twenty":-25.922457,"median":-10.973777,"eighty":-1.629248,"marketCap":4351379},{"date":"2023-09-22","current":-0.313422,"twenty":-25.608909,"median":-10.850476,"eighty":-1.618329,"marketCap":3966668},{"date":"2023-09-29","current":-0.321326,"twenty":-23.64226,"median":-10.850476,"eighty":-1.601441,"marketCap":4066710},{"date":"2023-10-06","current":-0.289162,"twenty":-22.775869,"median":-10.688976,"eighty":-1.580196,"marketCap":3659632},{"date":"2023-10-13","current":-0.282767,"twenty":-22.573417,"median":-10.456607,"eighty":-1.555984,"marketCap":3578704},{"date":"2023-10-20","current":-0.29562,"twenty":-21.87715,"median":-10.357272,"eighty":-1.530122,"marketCap":3741373},{"date":"2023-10-27","current":-0.411298,"twenty":-20.708929,"median":-10.28233,"eighty":-1.525237,"marketCap":5205388},{"date":"2023-11-03","current":-0.385592,"twenty":-20.392025,"median":-10.008413,"eighty":-1.495062,"marketCap":4880052},{"date":"2023-11-10","current":-0.347032,"twenty":-20.25282,"median":-9.861161,"eighty":-1.453706,"marketCap":4392046},{"date":"2023-11-17","current":-0.527039,"twenty":-20.061981,"median":-9.742695,"eighty":-1.436505,"marketCap":6466068},{"date":"2023-11-24","current":-1.186185,"twenty":-20.052297,"median":-9.704796,"eighty":-1.418894,"marketCap":14552898},{"date":"2023-12-01","current":-0.739897,"twenty":-20.005723,"median":-9.704796,"eighty":-1.398059,"marketCap":9077550},{"date":"2023-12-08","current":-0.734025,"twenty":-19.855784,"median":-9.614269,"eighty":-1.379383,"marketCap":9005506},{"date":"2023-12-15","current":-0.757514,"twenty":-19.851774,"median":-9.529855,"eighty":-1.357844,"marketCap":9293682},{"date":"2023-12-22","current":-0.645942,"twenty":-19.450728,"median":-9.294762,"eighty":-1.3426,"marketCap":7924845},{"date":"2023-12-29","current":-0.734025,"twenty":-19.297293,"median":-9.178577,"eighty":-1.336307,"marketCap":9005506},{"date":"2024-01-05","current":-0.88681,"twenty":-18.799586,"median":-9.116636,"eighty":-1.327539,"marketCap":10879973},{"date":"2024-01-12","current":-0.924547,"twenty":-18.612428,"median":-9.098246,"eighty":-1.320866,"marketCap":11342950},{"date":"2024-01-19","current":-0.793298,"twenty":-18.4748,"median":-9.093511,"eighty":-1.311971,"marketCap":9732698},{"date":"2024-01-26","current":-0.812646,"twenty":-18.270731,"median":-8.999403,"eighty":-1.29484,"marketCap":9970081},{"date":"2024-02-02","current":-0.973886,"twenty":-18.114699,"median":-8.888116,"eighty":-1.287424,"marketCap":11948272},{"date":"2024-02-09","current":-0.838445,"twenty":-18.019487,"median":-8.794971,"eighty":-1.269673,"marketCap":10286591},{"date":"2024-02-16","current":-0.825545,"twenty":-17.817247,"median":-8.794971,"eighty":-1.256593,"marketCap":10128336},{"date":"2024-02-23","current":-0.780398,"twenty":-17.732346,"median":-8.790393,"eighty":-1.250053,"marketCap":9574443},{"date":"2024-03-01","current":-0.780398,"twenty":-17.646021,"median":-8.785645,"eighty":-1.245038,"marketCap":9574443},{"date":"2024-03-08","current":-0.806197,"twenty":-17.646021,"median":-8.666669,"eighty":-1.242787,"marketCap":9890953},{"date":"2024-03-15","current":-1.202078,"twenty":-17.560637,"median":-8.610667,"eighty":-1.232053,"marketCap":12640641},{"date":"2024-03-22","current":-1.061836,"twenty":-17.368294,"median":-8.491696,"eighty":-1.227587,"marketCap":11165900},{"date":"2024-03-28","current":-1.202078,"twenty":-17.227608,"median":-8.487276,"eighty":-1.21683,"marketCap":12640641},{"date":"2024-04-05","current":-1.282217,"twenty":-17.050112,"median":-8.393504,"eighty":-1.215841,"marketCap":13483351},{"date":"2024-04-12","current":-1.151992,"twenty":-16.459254,"median":-8.335718,"eighty":-1.212048,"marketCap":12113948},{"date":"2024-04-19","current":-1.051818,"twenty":-16.10474,"median":-8.21272,"eighty":-1.209834,"marketCap":11060561},{"date":"2024-04-26","current":-1.592754,"twenty":-15.910707,"median":-7.968666,"eighty":-1.204842,"marketCap":16748850},{"date":"2024-05-03","current":-1.151992,"twenty":-15.82702,"median":-7.731497,"eighty":-1.203538,"marketCap":12113948},{"date":"2024-05-10","current":-1.101905,"twenty":-15.82702,"median":-7.634408,"eighty":-1.200338,"marketCap":11587254},{"date":"2024-05-17","current":-1.061836,"twenty":-15.734838,"median":-7.48459,"eighty":-1.18456,"marketCap":11165900},{"date":"2024-05-24","current":-0.858149,"twenty":-15.582152,"median":-7.430234,"eighty":-1.178636,"marketCap":10834083},{"date":"2024-05-31","current":-0.715889,"twenty":-15.563236,"median":-7.382,"eighty":-1.173177,"marketCap":9038058},{"date":"2024-06-07","current":-0.658318,"twenty":-15.563236,"median":-7.319625,"eighty":-1.165754,"marketCap":8311221},{"date":"2024-06-14","current":-0.711685,"twenty":-15.563236,"median":-7.290579,"eighty":-1.161858,"marketCap":8984974},{"date":"2024-06-21","current":-0.630227,"twenty":-15.512687,"median":-7.276703,"eighty":-1.151992,"marketCap":7956573},{"date":"2024-06-28","current":-0.631856,"twenty":-15.351334,"median":-7.261532,"eighty":-1.146431,"marketCap":7977141},{"date":"2024-07-05","current":-0.62594,"twenty":-15.258759,"median":-7.232486,"eighty":-1.131572,"marketCap":7902447},{"date":"2024-07-12","current":-0.703024,"twenty":-15.199238,"median":-7.174394,"eighty":-1.12194,"marketCap":8875638},{"date":"2024-07-15","current":-0.678244,"twenty":-15.199238,"median":-7.116302,"eighty":-1.119798,"marketCap":8562788},{"date":"2024-08-02","current":-0.716281,"twenty":-14.887513,"median":-6.941989,"eighty":-1.109939,"marketCap":9043003},{"date":"2024-08-09","current":-0.651797,"twenty":-14.669052,"median":-6.792928,"eighty":-1.091888,"marketCap":8228892},{"date":"2024-08-16","current":-0.751707,"twenty":-14.498482,"median":-6.738702,"eighty":-1.08187,"marketCap":8549966},{"date":"2024-08-23","current":-0.748193,"twenty":-14.327911,"median":-6.622518,"eighty":-1.078179,"marketCap":8510005},{"date":"2024-08-30","current":-0.721532,"twenty":-14.296916,"median":-6.562136,"eighty":-1.072328,"marketCap":8206761},{"date":"2024-09-06","current":-0.68602,"twenty":-14.296916,"median":-6.469219,"eighty":-1.069821,"marketCap":7802835},{"date":"2024-09-13","current":-0.727328,"twenty":-14.296916,"median":-6.411345,"eighty":-1.061836,"marketCap":8272684},{"date":"2024-09-20","current":-0.696727,"twenty":-14.296916,"median":-6.353237,"eighty":-1.054133,"marketCap":7924624},{"date":"2024-09-27","current":-0.695504,"twenty":-14.296916,"median":-6.321565,"eighty":-1.044289,"marketCap":7910709},{"date":"2024-10-04","current":-0.671793,"twenty":-14.118204,"median":-6.222154,"eighty":-1.036389,"marketCap":7641025},{"date":"2024-10-11","current":-0.50013,"twenty":-14.066248,"median":-6.067323,"eighty":-1.01984,"marketCap":5688519},{"date":"2024-10-18","current":-0.576109,"twenty":-14.066248,"median":-5.964847,"eighty":-1.014835,"marketCap":6552704},{"date":"2024-10-25","current":-0.757678,"twenty":-13.83181,"median":-5.814279,"eighty":-0.991815,"marketCap":8617878},{"date":"2024-10-31","current":-0.758731,"twenty":-13.730013,"median":-5.719235,"eighty":-0.980335,"marketCap":8629864},{"date":"2024-11-08","current":-0.571578,"twenty":-13.730013,"median":-5.630104,"eighty":-0.95093,"marketCap":6501164},{"date":"2024-11-15","current":-0.58064,"twenty":-13.64563,"median":-5.578452,"eighty":-0.920835,"marketCap":6604243},{"date":"2024-11-22","current":-0.799583,"twenty":-13.418762,"median":-5.497016,"eighty":-0.900947,"marketCap":6591059},{"date":"2024-11-29","current":-0.787271,"twenty":-13.355558,"median":-5.239709,"eighty":-0.895748,"marketCap":6489564},{"date":"2024-12-06","current":-0.794995,"twenty":-13.233835,"median":-3.78108,"eighty":-0.88234,"marketCap":6553235},{"date":"2024-12-13","current":-0.764989,"twenty":-13.105921,"median":-3.672532,"eighty":-0.851444,"marketCap":6305897},{"date":"2024-12-20","current":-0.769,"twenty":-12.89,"median":-3.527801,"eighty":-0.838445,"marketCap":6338957},{"date":"2024-12-27","current":-0.830348,"twenty":-12.631501,"median":-3.093611,"eighty":-0.825442,"marketCap":6844653},{"date":"2025-01-03","current":-0.952598,"twenty":-12.48183,"median":-2.023095,"eighty":-0.825442,"marketCap":7852372},{"date":"2025-01-10","current":-0.793212,"twenty":-12.48183,"median":-1.965726,"eighty":-0.824584,"marketCap":6538542},{"date":"2025-01-17","current":-0.818613,"twenty":-12.48183,"median":-1.915211,"eighty":-0.816226,"marketCap":6747922},{"date":"2025-01-24","current":-0.79247,"twenty":-12.48183,"median":-1.86954,"eighty":-0.811335,"marketCap":6532419},{"date":"2025-01-31","current":-0.772417,"twenty":-12.48183,"median":-1.845312,"eighty":-0.806197,"marketCap":6367119},{"date":"2025-02-07","current":-0.680321,"twenty":-12.48183,"median":-1.822285,"eighty":-0.800781,"marketCap":5607963},{"date":"2025-02-14","current":-0.62239,"twenty":-12.48183,"median":-1.794164,"eighty":-0.798943,"marketCap":5130429},{"date":"2025-02-21","current":-0.868969,"twenty":-12.48183,"median":-1.774601,"eighty":-0.794876,"marketCap":7163009},{"date":"2025-02-28","current":-1.185362,"twenty":-12.48183,"median":-1.738663,"eighty":-0.794876,"marketCap":9771079},{"date":"2025-03-07","current":-0.94517,"twenty":-12.48183,"median":-1.686929,"eighty":-0.794817,"marketCap":7791150},{"date":"2025-03-14","current":-1.021967,"twenty":-12.48183,"median":-1.674611,"eighty":-0.794817,"marketCap":8424189},{"date":"2025-03-21","current":-0.987802,"twenty":-12.48183,"median":-1.658971,"eighty":-0.794817,"marketCap":8142566},{"date":"2025-03-28","current":-1.186848,"twenty":-12.48183,"median":-1.64007,"eighty":-0.794817,"marketCap":9783324},{"date":"2025-04-04","current":-1.358413,"twenty":-12.48183,"median":-1.633375,"eighty":-0.794817,"marketCap":11197559},{"date":"2025-04-11","current":-1.559687,"twenty":-12.48183,"median":-1.622615,"eighty":-0.794876,"marketCap":12856684},{"date":"2025-04-17","current":-2.422481,"twenty":-12.48183,"median":-1.616463,"eighty":-0.794876,"marketCap":11877127},{"date":"2025-04-25","current":-2.795995,"twenty":-12.48183,"median":-1.615552,"eighty":-0.794817,"marketCap":13708421},{"date":"2025-05-02","current":-5.324769,"twenty":-12.48183,"median":-1.615552,"eighty":-0.794817,"marketCap":15499093},{"date":"2025-05-09","current":-6.823976,"twenty":-12.48183,"median":-1.615552,"eighty":-0.794817,"marketCap":19862916},{"date":"2025-05-16","current":-6.668915,"twenty":-12.48183,"median":-1.615552,"eighty":-0.794817,"marketCap":19411570},{"date":"2025-05-23","current":-6.755518,"twenty":-12.48183,"median":-1.615552,"eighty":-0.794817,"marketCap":19663651},{"date":"2025-05-30","current":-7.816302,"twenty":-12.357356,"median":-1.615552,"eighty":-0.794817,"marketCap":22751332},{"date":"2025-06-06","current":-8.374609,"twenty":-12.307084,"median":-1.615552,"eighty":-0.794817,"marketCap":24376428},{"date":"2025-06-13","current":-10.328685,"twenty":-11.690443,"median":-1.615552,"eighty":-0.794817,"marketCap":30064261},{"date":"2025-06-20","current":-10.831161,"twenty":-11.321673,"median":-1.612414,"eighty":-0.794757,"marketCap":31526846},{"date":"2025-06-27","current":-12.22693,"twenty":-11.220378,"median":-1.612414,"eighty":-0.794757,"marketCap":35589584},{"date":"2025-07-03","current":-17.363357,"twenty":-11.220378,"median":-1.612414,"eighty":-0.794757,"marketCap":50540460},{"date":"2025-07-11","current":-18.703294,"twenty":-11.220378,"median":-1.612414,"eighty":-0.794757,"marketCap":54440689},{"date":"2025-07-18","current":-19.987401,"twenty":-11.220378,"median":-1.612414,"eighty":-0.794757,"marketCap":58178408},{"date":"2025-07-25","current":-18.144987,"twenty":-11.220378,"median":-1.612414,"eighty":-0.794757,"marketCap":52815594},{"date":"2025-08-01","current":-13.399375,"twenty":-11.220378,"median":-1.612414,"eighty":-0.794757,"marketCap":39002284}],"updateTime":1754246992484}}}